Adamis Pharmaceuticals Co. (NASDAQ:ADMP) Short Interest Down 32.2% in April

Adamis Pharmaceuticals Co. (NASDAQ:ADMPGet Rating) was the target of a large decline in short interest during the month of April. As of April 30th, there was short interest totalling 799,900 shares, a decline of 32.2% from the April 15th total of 1,180,000 shares. Based on an average daily trading volume, of 1,560,000 shares, the days-to-cover ratio is currently 0.5 days.

Institutional Investors Weigh In On Adamis Pharmaceuticals

A hedge fund recently raised its stake in Adamis Pharmaceuticals stock. State Street Corp increased its position in Adamis Pharmaceuticals Co. (NASDAQ:ADMPGet Rating) by 13.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 475,373 shares of the specialty pharmaceutical company’s stock after acquiring an additional 55,168 shares during the quarter. State Street Corp owned about 0.32% of Adamis Pharmaceuticals worth $271,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 8.57% of the company’s stock.

Analysts Set New Price Targets

Separately, assumed coverage on shares of Adamis Pharmaceuticals in a research report on Friday, May 5th. They set a “hold” rating for the company.

Adamis Pharmaceuticals Price Performance

NASDAQ ADMP opened at $0.08 on Friday. Adamis Pharmaceuticals has a 52 week low of $0.07 and a 52 week high of $0.55. The company has a 50-day moving average price of $0.11 and a 200-day moving average price of $0.16.

About Adamis Pharmaceuticals

(Get Rating)

Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets.

Featured Stories

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with's FREE daily email newsletter.